which was slowly infused. Fifteen minutes later, 30 mg of d-fenfiuramine or placebo was administered orally. The two tests were run in random order and were separated by at least five days. Further blood specimens were drawn immediately before the drug or placebo administration (T=0) and after 60, 120, 180, 240 and 300 minutes. For the duration of the test, subjects rested (but did not sleep) and fasted except for water.
Drug treatment and rating scales
After the neuroendocrine test, all patients underwent a treatment with fiuvoxamine maleate. This drug was started at a dose of
SOmg at bedtime. After three days, dosage
was increased to SO mg twice a day. There after, in the absence of disturbing side effects, it could be increased by SO mg every three days up to a maximum dosage of 300 mg/day, according to the judgement of the clinician in charge of the patient. At the end of the 10th week, the dosage of fluvoxamine ranged between 150 and 300 mg/day (mean (s.d.) 220 (59)). Before the neuroendocrine test and after the 10-week drug treatment, psychopatholo gical assessment was performed using the Yale-Brown Obsessiveâ€"CompulsiveScale (Y-. BOCS; Goodman et a!, 1989) . Concomitant depressive symptoms were explored by the 21-item Hamilton Depression Rating Scale (HDRS; Hamilton, 1960) . At the end of the 10th week of therapy, the clinical response was quantified as the percentage change in the pretreatment Yâ€"BOCS total score.
Despite the unequivocal evidence of the anti-obsessive activity of drugs that block (more or less selectively) serotonin (S-HT) reuptake, an underlying alteration of sero tonergic transmission has not been convin cingly demonstrated in obsessive-compulsive disorder (OCD). Recently, efforts to assess brain serotonergic function in OCD have turned to the evaluation of neuroendocrine responses of OCD patients to pharmacolo gical S-HT challengers. (Gorard et a!, 1993) , a response which is considered an index of central S-I-IT respon sivity and activity. Studiesassessing hormonal responses to d-fenfluramine in OCD patients have given conflicting results; in particular, PRL response has been found to be either blunted (Lucey et a!, 1992) or enhanced (Roberts et a!, 1996) . In the present study,
D-fenfluramine releases neural S-HT
we assessed PRL responseto d-fenfiuramine in a sample of drug-free OCD patients, and investigated possible relationships between this response and: (a) patients' clinical char acteristics; and (b) the outcome of a 10-week treatment with the selective serotonin reup take inhibitor (SSRI) fluvoxamine.
METHOD Subjects
Twenty out-patients who met DSMâ€"IV criteria for OCD (American Psychiatric Association, 1994) and 20 healthy subjects gave their informed consent to participate in the study. The patient group consisted of 10 men and 10 women aged 18â€"64 years. All of them had been drug-free for at least three weeks before the beginning of the study Psychopathological assessment was performed before and after therapy.
Results PRLresponse inOCD patients
wasbluntedunder the drug-free condition; 
P=0.Ol v.pretreatment values(c-pairedtest).

Biochemical methods
Blood was collected in tubes with lithium heparinasanticoagulant.Plasmawas separ ated by centrifugation at 3000 rpm and stored at â€"¿ 20 Â°Cuntil assayed for PRL.
Hormonal assays for each patient and his/her matched control were run in the same lot. Plasma PRL levels were determined by a double-antibody radioimmunoassay method, using commercial kits purchased from Serono-Diagnostics (Milan, Italy). The lower and upper detection limits of the assay were 1.0 ng/ml and 200 ng/ml. Intra and inter-assay coefficients of variation were 2.1% and 4.6%.
Statistical analysis
Results were statistically analysed by conventional repeated measure analysis of variance (ANOVA), post hoc Tukey's test, and Student's f-test for paired data, where appropriate. Moreover, the integrated areas under the PRL time-curves (AUC) from T=0 to T=300 mm were calculated, and the net hormone response to d-fenfiuramine was expressed as the difference between the PRL AUC after d-fenfiuramine and the PRL AUC after placebo (AAUC; shaded areas in 
RESULTS
PRL response
Plasma PRL levels dropped between times Three-way ANOVA with repeated measures was used to control for group (patients V. healthy controls), drug (d fenfluramine v. placebo) and time effects. There was a significant time effect (F5,380=8.S76, P= 0.0000), a significant drug x time interaction (F5,@80=6.469, P=0.0000) and a significant group x drug x time interaction (F5,380=3.205, P=0.007), indicating that the timing of the PRL response to drug challenge was different between patients and healthy controls. Indeed, as compared with placebo, d fenfluramine induced a clear-cut increase in plasma PRL levelsin healthy subjects,but not in drug-free patients (Fig. 1) .
In order to exclude that the observed differences could be due to a different PRL response to placebo, a two-way ANOVA with repeated measures was performed on placebo data. This analysis showed no significant differences between OCD patients and healthy subjects with respect to plasma PRL levels after placebo.
When the data were analysed separately in the two groups, a clear gender effect emerged in healthy volunteers, but not in patients. Indeed,in normal subjects,three normal subjects than in patients (P=0.003; Student's f-paired test). Such a difference was also evident when data were analysed separately in the two sexes (P=0.009 for healthy women v. female patients; P=0.01 for healthy men v. male patients). Moreover, in healthy women, the mean PRL &AUC was significantly higher than in healthy men (P=0.01).
Response to treatment
Five patients (2 men and 3 women) did not complete the pharmacological trial. The IS patients who completed the 10-week fluvox amine treatment showed, as a group, significant decreases in the Yâ€"BOCStotal, obsession and compulsion scores as well as in the HDRS total score (Table 1) .
Correlations
In the patient group, statistically significant negative correlations emerged between the PRL I@AUCand the pre-treatment Yâ€"BOCS total (r= â€"¿ 0.51, P=0.009) (Fig. 2, top panel), obsession (r= â€"¿ 0.47, P=0.01) compulsion (r= â€"¿ 0.42, P=0.03) and HDRS total scores (r=â€"0.46, P=0.01). Moreover, a statistically significant negative correlation was found between the PRL L@AUC and the percentage change of the Yâ€"BOCStotal score after fluvoxamine treatment (r= â€"¿ 0.58, P=0.009) (Fig. 2, bottom panel) .
DISCUSSION
The main findings of this study are as follows.
(a) The PRL response to the S-HT releasing agent d-fenfluramine is blunted in drug free obsessiveâ€"compulsive patients, as compared with matched healthy subjects.
(b) In the patient group, the PRL response to d-fenfluramine, evaluated as L@AUC, is inversely correlated to pretreatment Yâ€"BOCS total, obsession and compul sion scores and to the HDRS total score.
(c) Plasma PRL L@AUCis inversely corre lated to the percentage change in the Yâ€" BOCS total score after a 10-week treatment with fluvoxamine.
(d) Among healthy subjects, but not patients, d-fenfluramine induces signifi cantly greater increases of plasma PRL levels in women than in men.
PRL response to d-fenfluramine in OCD
Inline with the report ofLuceyeta!(1992), we found a reduced PRL secretion after d-fen fluramine in drug-free obsessiveâ€"compulsive patients. The most likely explanation of this blunted PRL response is a decrease of central S-HT transmission. One can only speculate about whether S-HT alterations in OCD may result from dysfunctions in presynaptic or postsynaptic serotonergic regions, and about which S-HT receptor subtypes are involved.
It is widely acceptedthat d-fenfiuramine induced PRL release is mediated by post synaptic 5@@'2'5@'1C receptors and, in patients with OCD, blunted PRL responses tometa-chlorophenylpiperazineandMK-212, which are direct 5F2/5@1c receptor agonists, have been reported (Bastani et a!, 1990 ; Hollander ef a!, 1992). Therefore, although a presynaptic dysfunction cannot be excludedby present data,it seems possibleto suggestthat the blunted PRL responsein our patients results from a decreased postsynaptic receptor sensitivity to the d-fenfluramine released S-HT.
A possible alternative explanation of the blunted PRL response, that of a reduced secretory capacity of the pituitary lacto trophs, is not supported by currently avail able empirical evidence, since the PRL response to the thyrotropin-releasing hormone, a test which assesses the neuro secretory capacity of the lactotrophs, has been shown to be normal in such patients (Lucey et a!, 1993) .
PRL response to d-fenfluramine and psychopathology
In contrast to Lucey ef a! (1992), we found a negative correlation between plasma PRL response to d-fenfluramine and the degree of psychopathology in our patients. This dis crepancy may be due to the fact that those authors did not use a placebo-controlled design, thus adopting a quantification of PRL response different from ours.
Plasma PRL response to d-fenfluramine was related to the severity of both obsessive compulsive and depressive symptomatology. This is in line with the hypothesised involve ment of S-I-IT in the pathogenesis of both OCD and depression, and with the reported blunted PRL response to d-fenfluramine in patients with major depression (Lucey ef a!, 1992). The impaired PRL response to d fen.fluramine may not be specific to a nosological entity, but may reflect a central 
P<0.0I).
serotonergic dysfunction underlying several psychopathological manifestations (e.g. obsessive thoughts, suicidal ideation, aggres sion, depressed mood) occurring across different psychiatric disorders.
PRL response and outcome of fluvoxamine treatment
The negative correlation between plasma PRL response to d-fenfluramine and the clinical outcome of fluvoxamine treatment suggests that, in obsessiveâ€"compulsive patients, the greater the impairment of central serotonergic function (at least as assessedby the PRL responseto d-fenfluramine),the better the response to drugs that selectivelyblock the re uptake of S-HT. The only analogous results which can be found in the literature are those by ThorÃ©n et a!(1980) and Swedo etal(1992) , who reported a significant correlation between cerebrospinal fluid S-hydroxyindolacetic acid (CSF S-HIAA) levels and response to clomi pramine, although this relationship was posi tive. However, since increased CSF S-HIAA levels may produce a decreased availability of S-H@F atcentral synapses, these findings are not necessarily inconsistent with our data.
It is worth mentioning that, in our patients, no baseline clinical measure corre lated with the percentage improvement in the Yâ€"BOCS total score after treatment with fluvoxamine, whereas the PRL response to d-fenfluramine did. Whether this biological variable, which probably reflects brain serotonergic function, also has a discrimi nant power between patients who will and will not respond to treatment with SSRIs, needs to be assessedin future studies with larger patient samples.
PRL response in healthy subjects
The increased PRL response to d-fenflur amine in healthy women as compared with healthy men is in line with the reported enhanced responsivity to serotonergic agents in females (McBride et a!, 1990) . A facil itatory role of oestrogens on plasma PRL response to d-fenfluramine in normal women has been suggested on the basis of the variation of the PRL responsiveness to the S-HT releasing agent during the menstrual cycle (O'Keane et a!, 1991).
Possible limitations of the study
In the present study we used a fixed oral dose of d-fenfluramine for all the subjects. Obviously a weight-related dose would have been preferable. However, it must be mentioned that, in our samples, the hormonal responseto the S-HT releasing agent was not inversely related to body weight.
We did not measure plasma levels of d fen.fluramine and of its major metabolite d norfenfluramine. Hence it is possible that pharmacokinetic differences between healthy controls and OCD patients or between male and female subjects may have affected our findings. Even if, in healthy humans, no correlation has been reported between plasma levels of d-fenflur amine or d-norfenfluramine and the hormonal responses (Gorard ef a!, 1993) , the extent to which the bioavailability of the serotonergic agent affects the hormonal responses in OCD patients is clearly a 1996 ,accepted22 November 1996 crucial aspect to be addressed in future studies.
CONCLUSIONS
This study shows that plasma PRL response to d-fenfluramine is blunted in drug-free obsessiveâ€"compulsive patients. The degree of this dysfunction may predict the response to treatment with SSRIs, since the greater the impairment in this neuroendocrine response, the better the outcome of treat ment with fluvoxamine. McBride, R A.,Tierney@ H., DeMeo, M., it aI(I@90) Effects of ageand genderon @N5 serotonergicresponsivityin normal adults.Biological Psychiatry, 27, l143â€"llSS.
